Cargando…
Luteinizing hormone-releasing hormone analogues in early breast cancer: updated status of ongoing clinical trials.
In the year 2000, the ongoing meta-analysis of the Early Breast Cancer Trialists' Collaborative Group will be updated to include additional data from over 4000 patients treated with luteinizing hormone-releasing hormone analogues, principally goserelin. Four major international trials are curre...
Autor principal: | Kaufmann, M. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group|1
1998
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2062754/ https://www.ncbi.nlm.nih.gov/pubmed/9741782 |
Ejemplares similares
-
Luteinizing hormone-releasing hormone analogues--the rationale for adjuvant use in premenopausal women with early breast cancer.
por: Jonat, W.
Publicado: (1998) -
The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer
por: Milecki, Tomasz, et al.
Publicado: (2014) -
Future possibilities in the prevention of breast cancer: Luteinizing hormone-releasing hormone agonists
por: Spicer, Darcy V, et al.
Publicado: (2000) -
Effects of high doses of a series of new luteinizing hormone-releasing hormone analogues in intact female rats.
por: Maynard, P. V., et al.
Publicado: (1979) -
Bilateral injection-site granuloma by subcutaneous administration of luteinizing hormone-releasing hormone analogue: a case report
por: Kitazawa, Riko, et al.
Publicado: (2009)